Nektar surges again as alopecia drug shows new promise in extension study [Yahoo! Finance]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Yahoo! Finance
Dive Brief: An experimental autoimmune drug from Nektar Therapeutics helped people with alopecia areata who'd already responded to the treatment in a Phase 2 trial grow more hair as time went on, the company said Monday The data released Monday measured hair regrowth after 52 weeks of treatment with the therapy, known as rezpegaldesleukin. Nektar disclosed last year that the therapy failed to show a statistically significant benefit over a placebo after 36 weeks. The company, though, blamed that result on the inclusion of four patients that shouldn't have been eligible and said the findings supported additional development. Nektar's shares rose by nearly 25% in morning trading, changing hands at just over $105. Company shares haven't reached those heights since 2022, when a cancer drug it was developing with Bristol Myers Squibb failed in clinical testing , prompting layoffs and a restructuring . R ezpegaldesleukin has additionally shown promise against eczema , where study dat
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTRGlobeNewswire
- Nektar Therapeutics (NKTR) had its price target raised by Citigroup Inc. from $123.00 to $151.00. They now have a "buy" rating on the stock.MarketBeat
- Nektar (NKTR) Moves 18.3% Higher: Will This Strength Last? [Yahoo! Finance]Yahoo! Finance
- Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire
- Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire
NKTR
Earnings
- 3/12/26 - Beat
NKTR
Sec Filings
- 4/20/26 - Form 424B5
- 4/20/26 - Form 8-K
- 4/20/26 - Form 8-K
- NKTR's page on the SEC website